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Table 1
Effect of Statin on Immunomes
Statin vs.
non-statin
D30 (%)
P-value Median(Range)
Non-statin
exposed
Median(Range)
Statin exposed
Absolute
Lymphocyte
count
0.04688 850 (100-1300) 774.8 (109-2120)
DR+/14+ (absolute) 0.375 77.6 (43.1-86.3) 69.3 (19.2-92.1)
DR-/14+ (absolute) 0.1094 12.5 (2.7-34.4) 25.4 (1.8-78.6)
CD3+/56-/16- 0.04688 55 (15.4-78.2) 78.7 (52.5-95.8)
CD19+ 1 1 (0.2-2.0) 0.7 (0-39.4)
CD69 +/CD3+ 0.8655 3.2 (0.7-4.7) 2.7 (1.1-4.4)
CD3+/DR+ 1 5 (1.4-30.1) 5.1 (0.4-13.7)
CD3+/DR - 0.1563 48 (17.5-77.1) 70.1 (52.9-85.1)
CD3-/56+/16+ 0.03125 33.5 (16.5-42.2) 7.9 (2.7-21.0)
CD3-/56+/16+/314+ 0.03125 18.1 (6.5-34.0) 4.6 (0.7-10)
CD3-/56+/16+/117- 0.03125 22.4 (11.8-36.4) 6.3 (0.9-12.9)
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congenital immunosuppression.
Figure 1. TCR Repertoire Size: NRM v. other patients
The ﬁgure shows a comparison of TCR repertoire size, estimated based on
high-throughput sequencing of TCRb rearrangements, for all surviving
patients (N is indicated below each panel) with and without eventual non-
relapse mortality (NRM). TCR repertoire size values are given as quartiles for
both populations, with whiskers representing the maximum and minimum
values. Signiﬁcance is assessed using a one-tailed Mann-Whitney U test;
patients who went on to suffer from non-relapse mortality had signiﬁcantly
lower estimated repertoire sizes at 56 and 100 days post-transplant.
178
Impact of Atorvastatin On Cellular Immunome of
Patients Undergoing Allogeneic Hematopoietic Stem Cell
Transplantation (AHSCT)
Yvonne Efebera 1, Susan Geyer 2, Anissa Bingman 2,
Rhonda Kitzler 3, Patrick Elder 4, Carrie Hennelly 5,
Leslie A. Andritsos 1, Samantha Jaglowski 6, William Blum 1,
Rebecca Klisovic 1, Sam Penza 1, Sumithira Vasu 6,
Craig C. Hofmeister 1, Don M. Benson 1, Steven M. Devine 1,
Gerard Lozanski 3. 1 Division of Hematology, The Ohio State
University, Columbus, OH; 2Division of Biostatistics, The Ohio
State University, Columbus, OH; 3 Pathology, The Ohio State
University; 4 Blood and Marrow Transplantation Program,
Arthur G. James Cancer Institute, Columbus, OH; 5Medicine,
Division of Hematology, The Ohio State University; 6 Division of
Hematology, Ohio State University Medical Center, Columbus,
OH
Introduction: Acute graft-versus-host-disease (aGVHD) is
a frequent and lethal complication of HSCT despite current
prophylaxis. Release of pro-inﬂammatory cytokines lead to
damage of host tissues. Statins have been shown to reduce
pro-inﬂammatory cytokines while increasing the migration
of anti-inﬂammatory cytokines, especially when donor and
recipient are exposed to it, thus reducing aGVHD. We
present data on 14 patients enrolled in an ongoing phase II
study evaluating the efﬁcacy of atorvastatin as aGVHD
prophylaxis in patients undergoing matched-related donor
AHSCT.Method: In this phase II study donors receive atorvastatin 40
mg daily for at least 14 days before leukapheresis. Recipient
patients receive Atorvastatin 40mg daily starting at least 7
days before initiation of transplant conditioning regimen in
addition to standard approved GVHD prophylaxis with
tacrolimus and methotrexate. Atorvastatin is continued until
development of grade II or higher aGVHD, cessation of
aGVHD prophylaxis and or adverse event. We compared the
immune reconstitution pattern of patients on statin to those
of historic control patients not on statin matched to age, sex,
type of AHSCT and intensity of regimen.
Result: Median age of patients is 47 (range 27-67) and of
donor 46.5 (29-64). Ten patients received reduced intensity
AHSCT. Median neutrophil and platelets engraftment were
18.9 and 12.9 days. With a median follow up of 120 days (23-
287), two patients have relapsed one of whom died due to
disease. The median day 30 CD3 and CD34 chimerism were
81% and 100%. Two patients (14%) have developed grade II
aGVHD with no patients developing grade III or IV aGVHD.
Two patients developed chronic GVHD both mild and
limited. At day 30 post HSCT, compared to historic control,
patients exposed to statin had no difference in B cells(CD19+)
or total T cells (CD3+/DR+; CD3+/DR-), but a signiﬁcant
decline in NK cells, including total NK cells and NK cells
positive for CD314 (Table 1).
Conclusion: While this is a small sample, and no conclusion
can be deduced, it is interesting to note the signiﬁcant
difference in the number of NK cells in patients exposed to
statin as compared to historic control.179
Different Natural Killer (NK) Cell Subsets Elicit Unique
Target Induced Immune Responses: Implications for
Assessment of Posttransplant Functional Recovery of the
Relevant NK Cell Subsets and Their Impact On HCT
Outcomes
Rehan Mujeeb Faridi 1, Taylor J. Kemp 1, Abdelhamid Liacini 1,
Poonam Dharmani 1, Victor Lewis 2, Noureddine Berka 3,
Jan Storek 1,4, Faisal Khan 1,3. 1 Pathology and Laboratory
Medicine, University of Calgary, Calgary, AB, Canada;
2 Southern Alberta Children's Cancer Program, Alberta
Children's General Hospital, Calgary, AB, Canada; 3 Tissue
Typing Laboratory, Calgary Laboratory Services, Calgary, AB,
Canada; 4 Blood and Bone Marrow Transplant Program, Tom
Baker Cancer Centre/Foothills Hospital, Calgary, AB, Canada
